Erythropoietin (EPO) is the main signal driving erythropoiesis and often has been proposed as a possible adjuvant in therapies against COVID-19; among the genes screened, EPO showed down-regulation in agreement with the literature [39], possibly being a contributing cause to hypoxia in severe COVID-19. This evidence concerns the gene EPO and COVID-19.